DE69633617D1 - Il-17 receptor - Google Patents

Il-17 receptor

Info

Publication number
DE69633617D1
DE69633617D1 DE1996633617 DE69633617T DE69633617D1 DE 69633617 D1 DE69633617 D1 DE 69633617D1 DE 1996633617 DE1996633617 DE 1996633617 DE 69633617 T DE69633617 T DE 69633617T DE 69633617 D1 DE69633617 D1 DE 69633617D1
Authority
DE
Germany
Prior art keywords
receptors
receptor
isolated
ctla
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1996633617
Other languages
English (en)
Other versions
DE69633617T2 (de
DE69633617T3 (de
Inventor
Zhengbin Yao
Melanie K Spriggs
William C Fanslow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27021039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69633617(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DE69633617D1 publication Critical patent/DE69633617D1/de
Publication of DE69633617T2 publication Critical patent/DE69633617T2/de
Publication of DE69633617T3 publication Critical patent/DE69633617T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69633617T 1995-03-23 1996-03-21 Il-17 receptor Expired - Lifetime DE69633617T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41053595A 1995-03-23 1995-03-23
US410535 1995-03-23
US53876595A 1995-08-07 1995-08-07
PCT/US1996/004018 WO1996029408A1 (en) 1995-03-23 1996-03-21 Il-17 receptor
US538765 2000-03-30

Publications (3)

Publication Number Publication Date
DE69633617D1 true DE69633617D1 (de) 2004-11-18
DE69633617T2 DE69633617T2 (de) 2005-11-03
DE69633617T3 DE69633617T3 (de) 2010-05-20

Family

ID=27021039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633617T Expired - Lifetime DE69633617T3 (de) 1995-03-23 1996-03-21 Il-17 receptor

Country Status (15)

Country Link
US (9) US5869286A (de)
EP (1) EP0817847B2 (de)
JP (1) JP4373495B2 (de)
KR (1) KR100467998B1 (de)
AT (1) ATE279517T1 (de)
AU (1) AU696775B2 (de)
CA (1) CA2215394C (de)
DE (1) DE69633617T3 (de)
DK (1) DK0817847T4 (de)
ES (1) ES2229264T5 (de)
MX (1) MX9707021A (de)
NO (1) NO974258L (de)
NZ (1) NZ306653A (de)
PT (1) PT817847E (de)
WO (1) WO1996029408A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
MX9707021A (es) * 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
DK0839196T3 (da) * 1995-07-19 2005-09-12 Inst Genetics Llc Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US7005412B1 (en) 1996-11-27 2006-02-28 Immunex Corporation Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins
EP0959897B1 (de) * 1996-11-27 2009-04-22 Immunex Corporation Verfahren zur regulierung der stickstoffmonoxid-erzeugung
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
EP1015488B1 (de) * 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Interleukin-17 rezeptor-ähnliches protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1042505A1 (de) * 1997-12-22 2000-10-11 Stiftelsen Universitetsforskning Bergen ( Unifob) Verfahren zur prognose von krankheiten mittels fc receptor-genocharakterisierung
JP2003502006A (ja) * 1998-01-09 2003-01-21 イミュネックス・コーポレーション Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US8133734B2 (en) * 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
EP1171109A1 (de) * 1999-04-14 2002-01-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Zusammensetzungen die immunotoxine und hemmern der reifung der dendritische zellen enthalten zum induction von transplantatstoleranz
WO2000064327A2 (en) * 1999-04-26 2000-11-02 Duke University Inhibition of complement action
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
JP2016047051A (ja) * 1999-12-23 2016-04-07 ジェネンテック， インコーポレイテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
DK1897945T3 (da) * 1999-12-23 2012-05-07 Genentech Inc IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
PT1897944E (pt) * 1999-12-23 2011-11-28 Genentech Inc Polipéptidos homólogos de il-17 e suas utilizações terapêuticas
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO2001068859A2 (en) * 2000-03-16 2001-09-20 Amgen Inc. Il-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
AU2001274920A1 (en) * 2000-05-24 2001-12-03 Schering Corporation Mammalian receptor proteins; related reagents and methods
ES2382891T3 (es) 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002004519A2 (en) * 2000-07-06 2002-01-17 Zymogenetics, Inc. Murine cytokine receptor
AU2001277980A1 (en) * 2000-07-26 2002-02-05 Zymogenetics Inc. Human cytokine receptor
EP1326626B1 (de) * 2000-10-18 2020-04-01 Immunex Corporation Verfahren zur behandlung der rheumatoiden arthritis mittels il-17 antagonisten
US20040171109A1 (en) * 2000-11-10 2004-09-02 Dominik Haudenschild IL-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
EP1545578A4 (de) 2002-08-28 2010-07-07 Immunex Corp Zusammensetzungen und verfahren zur behandlung von herz-kreislauf-erkrankungen
AU2003298607B9 (en) * 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4441170B2 (ja) * 2002-11-28 2010-03-31 独立行政法人理化学研究所 Ｓ１２リボソームタンパク質に変異を有する大腸菌細胞抽出液及びそれを用いる無細胞系によるタンパク質の製造方法
DE602004022315D1 (de) * 2003-09-15 2009-09-10 Res Dev Foundation Cripto-antagonismus von activin und tgf-b signalisierung
CA2565801A1 (en) * 2004-05-28 2005-12-15 Applied Research Systems Ars Holding N.V. Use of il-17 in the treatment of fertility-related disorders
JP4903703B2 (ja) 2004-06-10 2012-03-28 ザイモジェネティクス， インコーポレイテッド 可溶性ＺｃｙｔｏＲ１４、抗ＺｃｙｔｏＲ１４抗体および結合相手ならびに炎症における使用方法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20060068434A1 (en) * 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
MX2007004597A (es) * 2004-10-18 2007-06-22 Zymogenetics Inc Zcytor21 soluble, anticuerpos anti-zcytor21 y moleculas de enlace y metodos de uso en inflamacion.
JP4868731B2 (ja) 2004-11-17 2012-02-01 独立行政法人理化学研究所 哺乳動物培養細胞由来の無細胞タンパク質合成システム
JP4590249B2 (ja) * 2004-11-17 2010-12-01 独立行政法人理化学研究所 糖タンパク質合成用の無細胞タンパク質合成システム
JP4787488B2 (ja) * 2004-11-19 2011-10-05 独立行政法人理化学研究所 直鎖状鋳型ｄｎａを用いた無細胞タンパク質合成方法及びそのための細胞抽出液
EP1849011A2 (de) * 2005-02-14 2007-10-31 University of Pittsburgh of the Commonwealth System of Higher Education Verwendung von il-17f zur diagnose und therapie von entzündungen der atemwege
BRPI0606991A2 (pt) * 2005-02-14 2009-08-18 Wyeth Corp métodos para triar compostos de teste capazes de antagonizar a sinalização de il-17f, para diagnosticar um distúrbio relacionado com a sinalização aumentada de il-17f em um indivìduo, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-21, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-23, para purificar a proteìna il-17a natural, e para isolar heterodìmeros de il-17 a/il-17f substancialmente isentos de homodìmeros de il-17a e homodìmeros de il-17f, uso de uma quantidade terapeuticamente eficaz de um antagonista da sinalização de il-17f, composição farmacêutica, adjuvante de vacina, anticorpo isolado, proteìnas il-17f e il-17a isoladas, e, heterodìmero de il-17a/il-17f
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
EP3673919A1 (de) 2005-06-14 2020-07-01 Amgen Inc. Selbstpuffernde proteinformulierungen
ATE445415T1 (de) 2005-09-01 2009-10-15 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
US20070197441A1 (en) * 2006-02-10 2007-08-23 Rixon Mark W Truncated il-17ra soluble receptor and methods of using in inflammation
WO2008039553A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
EP2029171A1 (de) * 2006-06-19 2009-03-04 Wyeth a Corporation of the State of Delaware Verfahren zur il-22- und il17-modulation
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
FR2910324B1 (fr) * 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
WO2008118930A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
CA2684329A1 (en) * 2007-04-20 2008-10-30 Amgen Inc. Identification and method for using the pre-ligand assembly domain of the il-17 receptor
JP2010534664A (ja) * 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物
EP2666783B1 (de) * 2007-09-25 2019-06-26 Genzyme Corporation Zusammensetzungen zur Hemmung der Interleukin-23 Wege
JP5704677B2 (ja) * 2007-11-05 2015-04-22 独立行政法人理化学研究所 膜タンパク質の製造方法
WO2009136976A2 (en) * 2008-02-21 2009-11-12 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
EP2166358A1 (de) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differentialdiagnostisches Biomarker von einen Schlaganfall imitierenden Bedingungen und Verfahren zur Verwendung dieser
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CA2755133A1 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
KR101766936B1 (ko) 2010-01-15 2017-08-09 키린-암젠, 인코포레이티드 항체 제제 및 치료 요법
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
WO2012145685A1 (en) 2011-04-20 2012-10-26 Amgen Inc. Autoinjector apparatus
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2809660B1 (de) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Makrocyclische verbindungen zur il-17-modulierung
ES2973257T3 (es) 2013-03-15 2024-06-19 Amgen Inc Casete de fármaco, autoinyector y sistema de autoinyector
WO2014143815A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
US11618777B2 (en) 2015-07-31 2023-04-04 Shigeyuki Yokoyama Method of manufacturing membrane protein and utilization thereof
CA3023451A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
CA3084486A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
CN111218425B (zh) 2019-01-17 2022-02-08 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
EP4028053A1 (de) 2019-09-11 2022-07-20 Bausch Health Ireland Limited Verfahren zur behandlung von nicht-alkoholischer fettleberkrankheit (nafld) mit il-17ra-antikörper
JP2022176672A (ja) * 2021-05-17 2022-11-30 国立大学法人北海道大学 ペプチド及び医薬用組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) * 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
MX9707021A (es) * 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
EP0959897B1 (de) * 1996-11-27 2009-04-22 Immunex Corporation Verfahren zur regulierung der stickstoffmonoxid-erzeugung
EP1326626B1 (de) * 2000-10-18 2020-04-01 Immunex Corporation Verfahren zur behandlung der rheumatoiden arthritis mittels il-17 antagonisten

Also Published As

Publication number Publication date
DE69633617T2 (de) 2005-11-03
ES2229264T3 (es) 2005-04-16
NZ306653A (en) 1999-03-29
ATE279517T1 (de) 2004-10-15
AU696775B2 (en) 1998-09-17
AU5526396A (en) 1996-10-08
EP0817847B1 (de) 2004-10-13
KR19980703061A (ko) 1998-09-05
NO974258D0 (no) 1997-09-15
ES2229264T5 (es) 2009-12-17
US20100233186A1 (en) 2010-09-16
CA2215394A1 (en) 1996-09-26
MX9707021A (es) 1997-11-29
EP0817847A1 (de) 1998-01-14
KR100467998B1 (ko) 2005-11-25
WO1996029408A1 (en) 1996-09-26
US6096305A (en) 2000-08-01
US6072037A (en) 2000-06-06
US6100235A (en) 2000-08-08
PT817847E (pt) 2005-02-28
US20090068737A1 (en) 2009-03-12
DE69633617T3 (de) 2010-05-20
CA2215394C (en) 2011-04-26
US6072033A (en) 2000-06-06
DK0817847T4 (da) 2009-10-05
US6191104B1 (en) 2001-02-20
US6197525B1 (en) 2001-03-06
EP0817847B2 (de) 2009-09-09
JP4373495B2 (ja) 2009-11-25
JPH11503309A (ja) 1999-03-26
DK0817847T3 (da) 2005-02-14
US5869286A (en) 1999-02-09
NO974258L (no) 1997-11-24

Similar Documents

Publication Publication Date Title
ATE279517T1 (de) Il-17 receptor
LU91758I9 (de)
ATE360032T1 (de) Cystein-reiche rezeptoren-train
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
DZ2026A1 (fr) Compositions vaccinantes.
EP0837927A4 (de) Monoklonale affen-antikörper gegen humane b7.1 und/oder b7.2 antigene, primatisierte derivate und pharmazeutische zusammensetzungen
IS4565A (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
CY1108074T1 (el) Ανοσολογικες μεθοδοι για τη ρυθμιση της μυοστατινης σε σπονδυλωτα
ITRM920476A0 (it) Formulazioni galeniche contenenti ciclosporina.
DE69226431D1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
TR199600786T1 (tr) Agiz yoluyla alinan yeni farmasötik dozaj formlari.
IT8920486A0 (it) Composizioni farmaceutiche.
FI893643A0 (fi) Farmaceutiska kompositioner.
DE69007908D1 (de) Shampoo-Zusammensetzung.
DE69600598D1 (de) Brennstoffzusammensetzungen
FI916067A0 (fi) Receptor foer humant interleukin 5.
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
TR199601012A2 (tr) Sampuan terkibi.
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie
DE69200508D1 (de) Modifiziertes Aethylen-alpha-olefin-nichtkonjugiertes Dien Copolymer Elastomer Zusammensetzung.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: BOCKHORNI & KOLLEGEN, 80687 MUENCHEN

8366 Restricted maintained after opposition proceedings